Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Risk factor analysis for the immunogenicity of adalimumab associated with decreased clinical response in Chinese patients with psoriasis
 
  • Details

Risk factor analysis for the immunogenicity of adalimumab associated with decreased clinical response in Chinese patients with psoriasis

Journal
Acta Dermato-Venereologica
Journal Volume
95
Journal Issue
6
Pages
711-716
Date Issued
2015
Author(s)
HSIEN-YI CHIU  
Wang, Ting-Shun
CHIH-CHIEH CHAN  
SUNG-JAN LIN  
TSEN-FANG TSAI  
DOI
10.2340/00015555-2069
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84932095819&doi=10.2340%2f00015555-2069&partnerID=40&md5=9891b9f10acbf547cfc61c507f628366
https://scholars.lib.ntu.edu.tw/handle/123456789/517617
Abstract
Although anti-drug antibodies against biologics have been associated with decreased clinical efficacy, the immunogenicity of biologics seems to vary between drugs, diseases and ethnicities. This study aims to investigate the predictors for the formation of anti-adalimumab antibodies (AAA) and the clinical consequences of AAA formation. In 53 Chinese psoriatic patients treated with adalimumab, AAA was detected in 50.9%. Differences in Psoriasis Area and Severity Index 75 (PASI75) response rates among patients with and without AAA were significant (44.4% vs. 88.5%; p = 0.001). Patients with AAA had significantly lower trough concentrations of adalimumab than those without AAA. Risk factor analysis showed that treatment interruption, low trough adalimumab concentration, absence of concomitant methotrexate use and biologics switching were associated with a higher AAA titre. The treatment pattern of biologics influences the risk of AAA formation, thereby leading to reduced efficacy of adalimumab. ? 2015 The Authors.
SDGs

[SDGs]SDG3

Other Subjects
adalimumab; biological product; drug antibody; methotrexate; tumor necrosis factor alpha inhibitor; adalimumab; antibody; immunosuppressive agent; methotrexate; nonsteroid antiinflammatory agent; adult; antibody production; antibody titer; Article; Chinese; drug blood level; drug efficacy; female; human; immunogenicity; loading drug dose; low drug dose; major clinical study; male; middle aged; minimum plasma concentration; monotherapy; priority journal; Psoriasis Area and Severity Index; psoriasis vulgaris; psoriatic arthritis; risk factor; statistical significance; treatment response; blood; China; drug combination; drug resistance; drug substitution; immunology; psoriasis; retrospective study; severity of illness index; Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies; China; Drug Resistance; Drug Substitution; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Methotrexate; Middle Aged; Psoriasis; Retrospective Studies; Risk Factors; Severity of Illness Index
Publisher
Medical Journals/Acta D-V
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science